Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer
Nature Medicine2010Vol. 16(2), pp. 214–218
Citations Over TimeTop 1% of 2010 papers
Yang Li, Lihua Zou, Qiyuan Li, Benjamin Haibe‐Kains, Ruiyang Tian, Yan Li, Christine Desmedt, Christos Sotiriou, Zoltán Szállási, J. Dirk Iglehart, Andrea L. Richardson, Zhigang Charles Wang
Related Papers
- → Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?(2003)94 cited
- → Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer(2008)21 cited
- → The Rat Model in the Comparative Evaluation of Anthracyclines Cardiotoxicity(1989)10 cited
- → The rat model in the comparative evaluation of anthracyclines cardiotoxicity.(1989)3 cited
- Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone.(1987)